In a recent exclusive with BioSpectrum Asia, Autolomous CEO and Co-founder, Alexander Seyf, shared a candid assessment of the European biotech landscape as we move into 2026.

While Europe maintains a strong scientific foundation, Alexander argues that global leadership in Cell and Gene Therapy (CGT) now depends on closing the “processing gap” through digital integration and radical collaboration. This includes:
Eliminating manual habits: Moving from pen-and-paper to real-time data capture to finally allow AI to make sense of thousands of autologous patient data points
The aviation “Black Box” model: Emulating the aviation industry’s approach to safety by adopting a system of shared intelligence where non-IP failures are disclosed to ensure the collective progress of the field
Purpose-driven digitization: Avoiding technology “overkill” by aligning tools to a clear scientific or processing purpose, before adopting popular, but overly complex or unnecessary digital systems
The Swiss ecosystem lesson: Prioritizing collective prosperity over isolated, zero-sum wins to ensure the entire biotech industry can scale globally

The leaders of 2026 will be those who connect the dots between scientific data, manufacturing visibility, and post-treatment efficacy.

To learn more, check out the full article here.